BRIEF — Kyverna Therapeutics Reports Positive One — Year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv — Cel In Stiff Person Syndrome And Generalized Myasthenia Gravis
Sept 24 (Reuters) — Kyverna Therapeutics, Inc.: Kyverna Therapeutics Reports Positive One-year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv-cel In Stiff Person Syndrome And Generalized Myasthenia Gravis Kyverna Therapeutics, - Miv-cel Well-tolerated In Gmg Trial With No High-grade